1. Home
  2. STDN vs GENB Comparison

STDN vs GENB Comparison

Compare STDN & GENB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Standard Nuclear Inc. Class A Common Stock

STDN

Standard Nuclear Inc. Class A Common Stock

SELL

Current Price

$12.48

Market Cap

1.9B

ML Signal

SELL

GENB

Generate Biomedicines Inc. Common Stock

HOLD

Current Price

$12.49

Market Cap

1.9B

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
STDN
GENB
Founded
2024
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Major Chemicals
Sector
Basic Materials
Exchange
Nasdaq
Nasdaq
Market Cap
1.9B
1.9B
IPO Year
2026
2026

Fundamental Metrics

Financial Performance
Metric
STDN
GENB
Price
$12.48
$12.49
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
9
6
Target Price
$17.56
★ $27.00
AVG Volume (30 Days)
439.1K
★ 1.1M
Earning Date
11-20-2026
11-03-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$439.23
N/A
Revenue Next Year
$259.21
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.05
$11.00
52 Week High
$17.34
$22.67

Technical Indicators

Market Signals
Indicator
STDN
GENB
Relative Strength Index (RSI) 46.23 32.99
Support Level $11.46 $11.82
Resistance Level $13.73 $13.96
Average True Range (ATR) 0.95 0.83
MACD 0.00 -0.21
Stochastic Oscillator 27.52 0.25

Price Performance

Historical Comparison
STDN
GENB

About STDN Standard Nuclear Inc. Class A Common Stock

Standard Nuclear Inc is an independent advanced nuclear fuel company. The company designs, engineers, and manufactures advanced nuclear fuels, with a primary focus on TRISO fuel for advanced reactors. Its operations include industrial-scale TRISO fuel manufacturing and the development of fuel for advanced reactors that utilize TRISO fuel. The company operates in a single operating and reportable segment, as it is engaged in a single business activity of TRISO production. It derives revenue from fuel development and services agreements. Geographically, the maximum revenue is generated from the United States.

About GENB Generate Biomedicines Inc. Common Stock

Generate Biomedicines Inc is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company's single operating segment is engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its product candidates include: GB-0895, GB-4362, and GB-5267. Through the company's Generate Platform, it can generate medicines on demand across multiple therapeutic modalities with unprecedented speed representing a fundamental shift in drug discovery.

Share on Social Networks: